nAMD | BayerPRO Ireland

This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.

Neovascular age-related macular degeneration (nAMD)

EYLEA^® 8mg (aflibercept 114.3 mg/ml) is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME).

For those who want flexibity to optimise patient intervals to Q16 and beyond

Save sight

whilst minimising treatment burden

Flexibility to extend treatment

intervals as far as Q24

Suppress VEGF

with a safety profile comparable to EYLEA 2mg

With only 3 loading doses and as few as 8 injections over 2 years^‡§

^{* Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q24 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.}
^{† Extend treatment intervals across your nAMD clinic, as far as Q24, for your eligible nAMD patients.}
^{‡ Patients could receive as few as 8 injections per dosing schedule within the trial protocol.}
^{§ Loading doses refers to the initial monthly dosing phase.}

PULSAR

Optimise vision whilst minimising burden

Primary endpoint: mean change in BCVA from baseline to Week 48 (non-inferiority) with an optional 1-year open-label extension until Week 156

In PULSAR, lasting BCVA gains from baseline were non-inferior with EYLEA 8 mg vs EYLEA 2 mg and maintained through Week 156, with as few as 10 injections over 3 years*

*Includes 3 initial monthly doses.
^†eFAS, observed cases.

Week 156

Extend treatment intervals for eligible patients in your nAMD clinic

At Week 156, >8 in 10 patients in the EYLEA 2Q8→8 mg group achieved a last completed dosing interval of ≥Q12 at Week 156, within a year of switching (PULSAR)*

PULSAR - Last completed treatment intervals

Could having more patients reach longer intervals help streamline your clinic?

*Patients completing Week 156: 8Q12/8Q16 n=375; 2Q8→8 mg n=186.

Extend treatment intervals for eligible patients across your nAMD clinic

At Week 156, approximately one quarter of patients on EYLEA 8 mg (8Q12/8Q16) achieved a last assigned dosing interval* of Q24 (PULSAR)

Adapted from Wong TY. 2025.

eSAF, patients completing Week 156.

*Patients who were randomised to the 8Q12 or 8Q16 groups at the beginning of the PULSAR study and continued treatment with EYLEA 8 mg through the PULSAR extension study Week 156; patients misassigned are included here for completeness.

^†Values may not add up to 100% due to rounding.

^‡One patient had a missing value for this assessment.

^§Per protocol, patients in the 2Q8→8 mg group did not have sufficient time to complete a ≥Q20 treatment interval by Week 156; values may not add up to 100% due to rounding.

Week 96

Extend treatment intervals for eligible patients across your nAMD clinic

In PULSAR, ~8 out of 10 patients achieved a last assigned dosing interval of ≥Q16 at Week 96^*

^{*Patients completing Week 96: 8Q12 n=291; 8Q16 n=292.}

Extend treatment intervals beyond expectations

The first and only anti-VEGF for nAMD that allows for extension to treatment intervals of Q24 after reaching Q16^*

Week 48

Flexibility to extend treatment intervals for eligible nAMD patients

In PULSAR, ~8 out of 10 patients maintained 16-week treatment intervals from baseline through Week 48^*

^{*Patients completing Week 48: 2Q8 n=309; 8Q12 n=316; 8Q16 n=312.}

See how you could optimise your DME patient's treatment journey and your clinic's capacity with EYLEA 8mg

Dosing

Discover proactive dosing in nAMD and DME

Mechanism of Action (MoA)

Discover more about the MoA of EYLEA 8mg

Abbreviations

^2Q8^{, 2 mg every 8 weeks;}^8Q12^{, 8 mg every 12 weeks;}^8Q16^{, 8 mg every 16 weeks; 8 mg every 16 weeks;}^AE^{, adverse event;}^APTC^{, Anti-Platelet Trialists’ Collaboration;}^BCVA^{, best-corrected visual acuity;}^CI^{, confidence interval;}^CRT^{, central retinal thickness;}^CST^{, central subfield thickness;}^DME^{, diabetic macular oedema;}^DRM^{, dose regimen modification;}^E-DRM^{, extension phase dose regimen modification;}^eFAS^{, extension phase full analysis set;}^eSAF^{, extension phase safety analysis set;}^ETDRS^{, Early Treatment of Diabetic Retinopathy Study;}^FAS^{, full analysis set;}^ICE^{, intercurrent event;}^IOI^{, intraocular inflammation;}^IOP^{, intraocular pressure;}^IRF^{, intraretinal fluid;}^LOCF^{, last observation carried forward;}^LS^{, least squares;}^MMRM^{, mixed model for repeated measurements;}^MoA^{, mechanism of action;}^nAMD^{, neovascular (wet) agerelated macular degeneration;}^N-BL^{, new baseline;}^Q8^{, every 8 weeks;}^Q16^{, every 16 weeks;}^Q20^{, every 20 weeks;}^Q24^{, every 24 weeks;}^SAE^{, serious adverse event;}^SD^{, standard deviation;}^SmPC^{, Summary of Product Characteristics;}^SRF^{, subretinal fluid;}^T&E^{, treat and extend;}^TEAE^{, treatment-emergent adverse event;}^VEGF^{, vascular endothelial growth factor.}

PP-EYL_8mg-IE-0151-2 | August 2026

References

1
EYLEA® 114.3 mg/mL Summary of Product Characteristics.
2
Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
3
Lanzetta P, et al. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
4
Lanzetta P, et al. Lancet. 2024;403(10432):1141–1152.
5
Wong TY. Three-year outcomes of aflibercept 8 mg in nAMD: safety and efficacy results from the PULSAR extension study. Angiogenesis, Exudation, and Degeneration 2025. 8 February 2025. Virtual. Oral presentation.
6
Bayer Data on File. PP-EYL_8mg-GB-0741. October 2025.
7
Chaudhary V, et al. Early fluid resolution association with treatment interval maintenance at Week 48 in patients receiving aflibercept 8 mg: Phase 3 PULSAR trial. Presentation at AAO 2023. San Francisco, CA, USA, 3–6 November 2023.
8
Brown DM. Aflibercept 8 mg in patients with nAMD: 48-week results from the phase 3 PULSAR trial. Angiogenesis, exudation, and degeneration 2023. 10–11 February 2023. Virtual. Oral presentation.
9
ClinicalTrials.gov. NCT04423718. Available at: https://classic.clinicaltrials.gov/ct2/show/NCT04423718. Accessed: December 2025.
10
Sivaprasad S, et al. BCVA gains with aflibercept 8 mg maintained through Week 96 in PULSAR with extended treatment intervals in patients with nAMD. Presentation at ARVO 2024; Seattle, WA, USA, 5–9 May 2024.
11
Korobelnik J-F. Aflibercept 8 mg in patients with neovascular age-related macular degeneration: Phase 3 PULSAR trial 96-week results. AAO. 3–6 November 2023. San Francisco, USA. Oral presentation.

Neovascular age-related macular degeneration (nAMD)

For those who want flexibity to optimise patient intervals to Q16 and beyond

With only 3 loading doses and as few as 8 injections over 2 years‡§

PULSAR

Optimise vision whilst minimising burden

Extend treatment intervals for eligible patients in your nAMD clinic

Could having more patients reach longer intervals help streamline your clinic?

Extend treatment intervals for eligible patients across your nAMD clinic

Extend treatment intervals for eligible patients across your nAMD clinic

Extend treatment intervals beyond expectations

Flexibility to extend treatment intervals for eligible nAMD patients

Abbreviations

With only 3 loading doses and as few as 8 injections over 2 years^‡§